etrumadenant + nanoparticle albumin-bound paclitaxel

This is a **combination therapy** consisting of *etrumadenant*, a small molecule adenosine A2A/A2B receptor antagonist developed as an immuno-oncology agent, and *nanoparticle albumin-bound paclitaxel* (nab-paclitaxel), an antimicrotubule taxane chemotherapeutic formulated by binding paclitaxel to human serum albumin nanoparticles to enhance tumor delivery and reduce toxicity. Etrumadenant blocks adenosine-mediated immunosuppression in the tumor microenvironment, aiming to boost anti-tumor immune response, while nab-paclitaxel inhibits tumor cell division by stabilizing microtubules, preventing their dynamic reorganization. Nab-paclitaxel enables higher dose administration than conventional paclitaxel, with fewer hypersensitivity reactions and improved tumor targeting through albumin receptor-mediated transcytosis. This combination is under clinical investigation particularly for solid tumors, including breast and pancreatic cancers, leveraging dual mechanisms: immune modulation and cytotoxic microtubule stabilization[1][2][3][5][6][7].

Brand names

ABRAXANE

Other names

protein-bound paclitaxelnab-paclitaxelpaclitaxel NAB